| Literature DB >> 33854105 |
Rani Matuk1, Mandy Pereira2, Janette Baird3, Mark Dooner4, Yan Cheng4, Sicheng Wen4, Shyam Rao5, Peter Quesenberry1,4, Neha P Raukar3,6.
Abstract
Traumatic brain injury (TBI) is of significant concern in the realm of high impact contact sports, including mixed martial arts (MMA). Extracellular vesicles (EVs) travel between the brain and oral cavity and may be isolated from salivary samples as a noninvasive biomarker of TBI. Salivary EVs may highlight acute neurocognitive or neuropathological changes, which may be particularly useful as a biomarker in high impact sports. Pre and post-fight samples of saliva were isolated from 8 MMA fighters and 7 from controls. Real-time PCR of salivary EVs was done using the TaqMan Human Inflammatory array. Gene expression profiles were compared pre-fight to post-fight as well as pre-fight to controls. Largest signals were noted for fighters sustaining a loss by technical knockout (higher impact mechanism of injury) or a full match culminating in referee decision (longer length of fight), while smaller signals were noted for fighters winning by joint or choke submission (lower impact mechanism as well as less time). A correlation was observed between absolute gene information signals and fight related markers of head injury severity. Gene expression was also significantly different in MMA fighters pre-fight compared to controls. Our findings suggest that salivary EVs as a potential biomarker in the acute period following head injury to identify injury severity and can help elucidate pathophysiological processes involved in TBI.Entities:
Year: 2021 PMID: 33854105 PMCID: PMC8047010 DOI: 10.1038/s41598-021-87180-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Summary of control participant group.
| Control | Gender | Age |
|---|---|---|
| 1 | F | 22 |
| 2 | F | 22 |
| 3 | F | 25 |
| 4 | F | 33 |
| 5 | F | 23 |
| 6 | M | 22 |
| 7 | M | N/A |
Summary of Fighter Data: gender (male/female), outcome (win(W)/lose(L)/draw(D)/no contest(NC)), round of fight completion (1/2/3), method of outcome (Knockout(KO)/Technical Knockout(TKO)/Submission(S)/Judges’ Decision (D), Mechanism (P = punches, J = joint decision, C = choke, NA = not applicable), loss of consciousness (LOC = Yes/No).
| Fighter | Gender | Age | Outcome | Round | Method | Mechanism | LOC |
|---|---|---|---|---|---|---|---|
| 1 | M | 18–30 | W | 1 | S | J | N |
| 2 | M | 18–30 | L | 2 | TKO | P | N |
| 3 | M | 18–30 | W | 1 | S | C | N |
| 4 | F | 18–30 | W | 3 | D | NA | N |
| 5 | M | 18–30 | W | 3 | D | NA | N |
| 6 | F | 18–30 | L | 2 | TKO | P | N |
| 7 | F | 18–30 | W | 2 | TKO | P | N |
| 8 | M | 18–30 | L | 3 | TKO | P | N |
Figure 1TEM image of salivary EV, 21000 K (A). Representative image of salivary EV western blot. Western blot analysis of samples shows the presence of EV markers: CD9, CD63, CD81, HSP70, PDCD6IP, and negative for apoA-I (B).
List of filtered genes by statistical method.
| Group 1 | Group 2 | Group 3 | Gene full name |
|---|---|---|---|
| Wilcoxin .05 | Wilcoxin .10 | CI 0.05 | |
| ADRB1 | Adrenoreceptor Beta 1 | ||
| Adrenoreceptor Beta 2 | |||
| Arachidonate-5-Lipoxygenase | |||
| ALOX12 | Arachidonate-12-Lipoxygenase | ||
| Annexin A1 | |||
| ANXA3 | Annexin A3 | ||
| CASP1 | Caspase 1 | ||
| CYSLTR1 | Cysteinyl Leukotriene Receptor 1 | ||
| HPGD | 15-Hydroxyprostaglandin Dehydrogenase | ||
| Histamine Receptor H1 | |||
| HRH2 | Histamine Receptor H2 | ||
| ICAM1 | Intercellular Adhesion Molecule 1 | ||
| IL1R2 | Interleukin 1 Receptor Type 2 | ||
| ITGB1 | Integrin Subunit Beta 1 | ||
| Integrin Subunit Beta 2 | |||
| KLK1 | Kallikrein 1 | ||
| LTA4H | Leukotriene A4 Hydrolase | ||
| LTB4R2 | Leukotriene B4 Receptor 2 | ||
| LTB4R | Leukotriene B4 Receptor | ||
| MAPK14 | Mitogen-Activated Protein Kinase 14 | ||
| MAPK3 | Mitogen-Activated Protein Kinase 3 | ||
| Mitogen-Activated Protein Kinase 8 | |||
| NFKB1 | Nuclear Factor Kappa B Subunit 1 | ||
| Phosphodiesterase 4B | |||
| PDE4D | Phosphodiesterase 4D | ||
| PTAFR | Platelet Activating Factor Receptor | ||
| PTGDR | Prostaglandin D2 Receptor | ||
| TBXAS1 | Thromboxane A Synthase 1 | ||
| TNF | Tumor Necrosis Factor | ||
| TNFRSF1A | TNF Receptor Superfamily Member 1A | ||
| TNFRSF1B | TNF Receptor Superfamily Member 1B |
Group 1 genes with p value < 0.05, Group 2 genes with p value < 0.10, Group 3 genes with a confidence interval of 0.05.
Figure 2Pre fighter versus post fighter relative filtered gene expression—fold change. Seven key genes are highlighted in green.
Figure 3Pre fighter versus control relative filtered gene expression—fold change. Seven key genes are highlighted in green.
Standardized gene signals of filtered genes where signal is absolute value [Median ddCT/St Dev ddCT].
| Fighter | Median | SD | Signal31 | Rank31 | Median | SD | Signal7 | Rank7 |
|---|---|---|---|---|---|---|---|---|
| DDCT_31 | DDCT_31 | DDCT_7 | DDCT_7 | |||||
| 1_MMA | − 0.76 | 4.80 | 0.16 | 7 | 0.29 | 6.04 | 0.05 | 8 |
| 2_MMA | 1.81 | 4.73 | 0.38 | 1 | 1.84 | 0.25 | 7.47 | 1 |
| 3_MMA | 3.93 | 5.69 | 0.69 | 6 | 0.52 | 7.82 | 0.07 | 6 |
| 4_MMA | 1.11 | 4.16 | 0.27 | 4 | 1.60 | 10.17 | 0.16 | 4 |
| 5_MMA | 0.64 | 5.07 | 0.13 | 3 | 1.39 | 5.25 | 0.26 | 2 |
| 6_MMA | − 0.39 | 6.59 | 0.06 | 5 | − 0.88 | 6.67 | 0.13 | 5 |
| 7_MMA | 0.46 | 6.06 | 0.08 | 8 | − 0.65 | 12.23 | 0.05 | 7 |
| 8_MMA | 1.82 | 4.14 | 0.44 | 2 | 1.22 | 5.93 | 0.21 | 3 |
Signal of 31 genes with a confidence interval of 0.05. Signal of 7 genes with p value < 0.10.
Figure 4Fighter Level Delta Delta CT (cycle threshold) for seven key genes.